ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction

Jianqing She¹,², Bowen Lou¹,², Hui Liu³, Bo Zhou⁴, Gulinigaer Tuerhong Jiang¹,², Yongbai Luo¹,², Haoyu Wu¹,², Chen Wang¹,² and Zuyi Yuan¹,²*

¹Cardiovascular Department, First Affiliated Hospital of Xi’an Jiaotong University, Yanta West 237, Xi’an, 710061, China; ²Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi’an, China; ³Biobank, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China; and ⁴Respiratory Department, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Abstract

Aims This study aimed to compare the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) therapy with angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy for cardiovascular outcomes in patients with acute myocardial infarction (AMI).

Methods and results Data were collected from the Biobank of the First Affiliated Hospital of Xi’an Jiaotong University between January 2016 and December 2020. A total of 7556 AMI patients were screened for eligibility. Propensity score matching based on age, sex, blood pressure, kidney function, baseline left ventricular ejection fraction (LVEF), and cardiovascular medication were conducted, resulting in 291 patients with AMI being assigned to ARNI, ACEI, and ARB group, respectively. Patients receiving ARNI had significantly lower rates of the composite cardiovascular outcome than ACEI (hazard ratio [HR] 0.51, [95% confidence interval (CI), 0.27–0.95], P = 0.02), and ARB users [HR 0.47, (95%CI, 0.24–0.90), P = 0.02]. Patients receiving ARNI showed lower rates of cardiovascular death than ACEI [HR 0.37, (95%CI, 0.18–0.79), P = 0.01] and ARB users [HR 0.41, (95%CI, 0.18–0.95), P = 0.04]. Subgroup analysis indicated that patients with LVEF no more than 40% tend to benefit more from ARNI as compared with ACEI [HR 0.30, (95%CI, 0.11–0.86), P = 0.01] or ARB [HR 0.21, (95%CI, 0.04–1.1), P = 0.05]. Patients aged no more than 60 years exhibited reduced composite endpoints [HR for ARNI vs. ARB: 0.11, (95%CI, 0.03–0.46), P = 0.002].

Conclusions In patients with AMI, ARNI was superior to ACEI/ARB in reducing the long-term adverse cardiovascular outcomes. Subgroup analysis further indicates that ARNI is more likely to benefit patients with LVEF less than 40% and aged less than 60 years.

Keywords Acute myocardial infarction; Sacubitril/valsartan (LCZ696); Angiotensin converting enzyme inhibitor (ACEI); Angiotensin receptor blockers (ARB)

Introduction

Ventricular remodelling after acute myocardial infarction (AMI) has been proven to be correlated to the occurrence of heart failure (HF) and the incidence of long-term cardiac events after AMI.¹–³ Despite advances in the treatment regime of cardiovascular disease, ventricular remodelling after AMI remains a major public health problem worldwide and exerts a substantial economic burden. Prompt initiation of guideline-proven therapies, including utilization of angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or angiotensin receptor-neprilysin inhibitor (ARNI), has resulted in reduced in-hospital mortality.⁴,⁵ However, although a number of clinical trials indicate the superiority of ARNI compared with ACEI or ARB among patients with HF with reduced ejection fraction (HFrEF), evidence is still lacking for the long-term benefits of ARNI over ACEI or ARB among AMI patients.

Patients surviving an AMI, particularly those with features of higher risk of subsequent HF development, constitute an expanding population of individuals in jeopardy of developing symptomatic HF or premature death.⁶ It is well established
that the mechanisms of ventricular remodelling after AMI involve activation of neuroendocrine system including renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system (SNS), and natriuretic peptide system.7 SNS augments RAAS activity, while natriuretic peptides-atrial natriuretic peptide and brain natriuretic peptide antagonize the RAAS and SNS by natriuresis and vasodilation. Conventionally, RAAS inhibition has focused on clinical utilization of ACEI and ARB, and recently, ARNI brings the latest addition to this armamentarium.8

Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor combining the valsartan with sacubitril, a neprilysin inhibitor. In the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial, ARNI therapy significantly reduced the risk of death and hospitalization for worsening HF compared with enalapril.9 Additionally, a number of studies have confirmed that in HF patients with reduced ejection fraction, sacubitril/valsartan can reduce N-terminal B-type natriuretic peptide levels, increase left ventricular ejection fraction (LVEF), and reverse ventricular remodelling, exerting more clinical and symptomatic benefits as compared to ACEI/ARB.10–14 Although increasing evidence support the use of ARNI therapy instead of ACEI or ARB for patients with HF, the evidence for AMI patients is still lacking. The Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after Myocardial Infarction (PARADISE-MI) trial has been recently published with regard to the study design and baseline characteristics.15 Yet more evidence based on real-world practice is still urgently needed.

As a result, the primary objective of the present study is to assess the long-term cardiovascular outcome of ARNI vs. ACEI/ARB among the AMI patients based on the real-world experience.

**Methods**

**Data collection and study design**

This is a triple-arm retrospective study. We collected the retrospective electronic medical records from the Biobank of the First Affiliated Hospital of Xi’an Jiaotong University, which contains de-identified data derived from raw medical records. The project was approved by the Institutional Ethical Board of the First Affiliated Hospital of Xi’an Jiaotong University. The disease was identified using International Classification of Diseases, Ninth Revision, Clinical Modification before 2015 and International Classification of Diseases, Tenth Revision, Clinical Modification diagnostic code after 2016.

**Figure 1** shows the flow chart of patient inclusion. A total of 7556 AMI patients from the biobank database between January 2016 and December 2020 were screened for eligibility. A total of 2085 patients without revascularization or without ARNI, ACEI, or ARB therapy were excluded to avoid potential treatment bias. The cohort entry date was the date of the first prescription of ARNI regardless of previous ACEI/ARB prescription. Propensity score matching (PSM) (1:1:1) based on age, sex, blood pressure, kidney function, baseline LVEF, and cardiovascular medication were conducted, resulting in 291 patients with AMI being assigned to each group. Patients with incomplete clinical data were excluded during the PSM. Patients switching to ACEI/ARB as indicated by the biobank database were also excluded from the subsequent analysis. Moreover, those patients without follow-up data were excluded, and the remaining patients were included in the clinical outcome analyses.

**Study cohorts and treatment**

Participants were allocated into ARNI vs. ACEI or ARB treatment groups, contingent on whether they began ARNI during hospitalization. Patients were prescribed with ARNI either due to evidence of left ventricular systolic dysfunction (LVEF ≤ 50%) and/or large area myocardial infarction with pulmonary congestion requiring intravenous treatment based on the Chinese Expert Consensus on Prevention and Treatment of Ventricular Remodelling after Acute Myocardial Infarction.16 The other two propensity score matched cohorts received ACEI or ARB therapy based on the present guidelines for the treatment of AMI.5

**Endpoints**

The primary endpoint was to determine whether sacubitril/valsartan would be non-inferior to ACEI or ARB in reducing the incidence of the composite outcome including cardiovascular death, myocardial infarction, HF hospitalization, and ischaemic stroke, based on a time-to-first event analysis. The first of the secondary outcomes was cardiovascular death. Additionally, secondary objectives were to assess the rehospitalization for worsening HF. The occurrence of myocardial infarction and stroke was diagnosed using the biobank data or from the patients’ follow-up claim. The definition of hospitalization for worsening HF was hospitalization with a combination of a diagnosis of HF. Each patient was followed until the day of outcome occurrence or death within 2 years after the cohort entry date or 31 March 2021, whichever came first.
Statistical analysis

Because patients receiving ARCI, ACEI, or ARB varied a lot on baseline characters, PSM was employed and covariates were age, sex, admission blood pressure, respiration rate, temperature, LVEF, baseline creatine, uric acid and haemoglobin levels, and eight types of cardiovascular medication. All eligible participants were propensity-matched 1:1:1 of ARNI: ACEI: ARB. The propensity score was calculated using the values of the covariates (Supporting Information, Figure S1).

The time from the first dose of ARNI, ACEI, or ARB to the first occurrence of a primary safety endpoint event was analysed with the use of a Cox proportional-hazards model, with ARNI as a covariate and with stratification to ACEI or ARB (no stratification for the comparison of ACEI with ARB), to provide a point estimate hazard ratio (HR) and a two-sided 95% confidence interval (CI). Cumulative event
|                      | Pre-match | Post-match | ARNI | ACEI | ARB | P value | ARNI | ACEI | ARB | P value |
|----------------------|-----------|------------|------|------|-----|---------|------|------|-----|---------|
| **Number**           | 385       | 4496       | 590  | 291  | 291 | NS      | 291  | 291  | 291 | NS      |
| **Age**              | 62.45 ± 12.056 | 61.44 ± 11.90 | 63.59 ± 6.36 | <0.001 | 61.82 ± 11.90 | 61.98 ± 12.52 | 62.13 ± 12.53 | NS |
| **Sex**              |           |            |      |      |     |         |      |      |     |         |
| Female               | 89, 23.1% | 865, 19.2% | 153, 25.9% | NS | 68.00, 23.4% | 63.00, 21.6% | 65.00, 22.3% | NS |
| Male                 | 296, 76.9% | 3631, 80.8% | 437, 74.1% | NS | 223.00, 76.6% | 228.00, 78.4% | 226.00, 77.7% | NS |
| **Medications**      |           |            |      |      |     |         |      |      |     |         |
| β-Blockers           |           |            |      |      |     |         |      |      |     |         |
| Loop diuretics       |           |            |      |      |     |         |      |      |     |         |
| Aldosterone          |           |            |      |      |     |         |      |      |     |         |
| Aspirin              | 95.1%     | 98.3%      | 95.4% | NS | 97.6% | 97.6% | 96.2% | NS |
| Ticagrelor           | 54.8%     | 52.5%      | 46.9% | NS | 57.0% | 55.3% | 50.2% | NS |
| Clopidogrel          | 54.8%     | 62.0%      | 66.6% | <0.05 | 56.4% | 56.4% | 61.9% | NS |
| Systolic BP (mmHg)   | 125.26 ± 23.90 | 125.65 ± 21.60 | 128.77 ± 24.44 | <0.01 | 117.33 ± 25.37 | 135.20 ± 14.48 | 119.83 ± 28.88 | NS |
| Diastolic BP (mmHg)  | 79.03 ± 15.34 | 78.80 ± 14.57 | 77.46 ± 14.12 | NS | 79.71 ± 15.80 | 78.95 ± 15.15 | 77.17 ± 14.31 | NS |
| Creatine (μmol/L)    | 72.88 ± 48.41 | 71.40 ± 57.62 | 84.76 ± 46.17 | <0.001 | 73.34 ± 48.33 | 71.23 ± 51.14 | 78.19 ± 60.95 | NS |
| Uric acid (μmol/L)   | 338.92 ± 107.97 | 332.25 ± 92.18 | 330.80 ± 95.91 | NS | 342.93 ± 108.52 | 341.59 ± 98.83 | 333.79 ± 99.71 | NS |
| Hb (g/L)             | 137.81 ± 20.08 | 141.52 ± 18.87 | 139.30 ± 17.32 | <0.001 | 138.41 ± 19.74 | 138.81 ± 20.40 | 138.88 ± 17.57 | NS |
| LVEF (%)             | 50% ± 12% | 52% ± 10% | 54% ± 12% | <0.001 | 50% ± 12% | 50% ± 12% | 53% ± 11% | NS |
| HbA1c (%)            | 6.64 ± 1.72 | 6.29 ± 1.46 | 6.54 ± 1.40 | <0.001 | 6.65 ± 1.75 | 6.33 ± 1.41 | 6.48 ± 1.35 | NS |
| NT-proBNP (pg/mL)    | 1287.00 [347.78, 3677.75] | 280.10 [87.91, 435.75] | 435.75 [168.35, 1434.75] | <0.001 | 956.78 [234.65, 3355.25] | 890.95 [180.28, 610.65] | 610.65 [166.38, 1920.50] | NS |
| D-dimer (mg/L)       | 1.58 ± 1.91 | 0.95 ± 2.50 | 1.10 ± 2.53 | <0.05 | 1.58 ± 1.92 | 1.35 ± 2.79 | 1.23 ± 3.78 | NS |
| TG (mmol/L)          | 1.42 ± 0.81 | 1.61 ± 1.21 | 1.51 ± 0.59 | <0.01 | 1.39 ± 0.77 | 1.57 ± 1.06 | 1.55 ± 1.14 | NS |
| LDL-C (mmol/L)       | 2.29 ± 0.86 | 2.41 ± 0.84 | 2.23 ± 0.80 | <0.001 | 2.33 ± 0.86 | 2.50 ± 0.92 | 2.34 ± 0.95 | NS |
| HDL-C (mmol/L)       | 0.93 ± 0.23 | 0.95 ± 0.23 | 0.93 ± 0.24 | NS | 0.94 ± 0.24 | 0.98 ± 0.24 | 0.94 ± 0.23 | NS |
| TC (mmol/L)          | 4.01 ± 1.13 | 4.13 ± 1.08 | 3.88 ± 1.02 | <0.001 | 4.08 ± 1.13 | 4.24 ± 1.15 | 4.08 ± 1.15 | NS |
| Lp(a) (mg/L)         | 331.35 ± 296.21 | 255.51 ± 234.51 | 280.19 ± 254.42 | <0.001 | 320.84 ± 286.51 | 276.32 ± 255.33 | 252.03 ± 226.42 | <0.05 |
| Homocystine (μmol/L) | 25.65 ± 17.59 | 24.18 ± 15.97 | 23.62 ± 13.57 | NS | 25.42 ± 17.78 | 25.05 ± 16.46 | 24.82 ± 16.97 | NS |

**Table 1** Baseline characteristics among the ARNI, ACEI, and ARB groups before and after propensity score matching.

ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitors; BP, blood pressure; Hb, haemoglobin; HbA1c, haemoglobin A 1c; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; Lp(a), lipoprotein a; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide; TC, total cholesterol; TG, triglyceride.

Data were presented mean ± standard deviation, number (%), or median [25th, 75th percentile].
rates were estimated at the 24 month follow-up with the use of the Kaplan–Meier method, and \(P\) values were calculated with the use of the two-sided log-rank test. One-way ANOVA was used to compare continuous variables or \(\chi^2\) test for categorical variables. Data were presented as frequencies and percentages for categorical variables and mean ± SD. for continuous variables, unless otherwise indicated. A two-sided \(P\) values of less than 0.05 were considered to indicate statistical significance. All the statistical analyses were performed using SPSS Version 25.0 (SPSS Inc, Chicago, IL).

**Results**

**Study cohort and baseline characteristics**

A total of 7556 AMI patients from the biobank database between January 2016 and December 2020 were screened for eligibility. After excluding those without revascularization or without ARNI, ACEI, or ARB therapy, the remaining 358 ARNI users, 4496 ACEI users and 590 ARB users were selected for PSM. Of these, 291 ARNI were successfully matched with 291 ACEI and ARB users, respectively. Characteristics of the cohorts before and after PSM are presented in Table 1. The matched groups were well-balanced in demographic and clinical characteristics, with the exception of other cardiovascular medications and lipoprotein a level. The mean duration of follow-up was 9.35 ± 25.74, 8.63 ± 34.91, and 9.21 ± 33.37 months, respectively. The mean ages were 61.82 ± 11.90, 61.98 ± 12.52, and 62.13 ± 12.53 years among the ARNI, ACEI, and ARB users, respectively. For other cardiovascular medications, beta-blockers were prescribed in 82.1%, 80.1%, and 75.3%; loop diuretics 58.1%, 60.1%, and 45.7%; and aldosterone antagonist 55.0%, 56.4%, and 38.5% of patients, respectively. The baseline brain natriuretic peptide levels were 956.78, 890.95, and 610.65 mg/dL. The baseline LVEF levels were 50 ± 12%, 50 ± 12%, 50 ± 12%, and 53 ± 11% (Table 1).

**Primary endpoints**

The primary composite endpoint, including cardiovascular death, myocardial infarction, HF hospitalization, and ischemic stroke, occurred in 16 (6.18%) ARNI users, 24 (11.21%) ACEI users, and 22 (12.72%) ARB users. Patients receiving ARNI had significantly lower rates of the composite outcome
than ACEI users [HR for ARNI vs. ACEI: 0.51, (95%CI, 0.27–0.95), P = 0.02] and ARB users [HR for ARNI vs. ARB: 0.47, (95%CI, 0.24–0.90), P = 0.02] (Figure 2, Table 1).

Secondary endpoints

Death from cardiovascular causes occurred in 9 (3.47%) patients in the ARNI group, 19 (8.88%) in the ACEI group, and 14 (8.09%) in the ARB group. Patients receiving ARNI had significantly lower rates of cardiovascular death than ACEI and ARB users [HR for ARNI vs. ACEI: 0.37, (95%CI, 0.18–0.79), P = 0.01; HR for ARNI vs. ARB: 0.41, (95%CI, 0.18–0.95), P = 0.04] (Figure 3). Cardiovascular death contributed most to the primary outcome benefits. But rates for myocardial infarction, HF hospitalization, ischaemic stroke, and rehospitalization showed no statistical difference (Table 2).

Subgroup analysis

The lower rate of primary composite endpoints was consistent across multiple subgroups. It is indicated that patients with cardiac ejection fraction no more than 40% tend to benefit more from ARNI as compared with ACEI [HR for ARNI vs. ACEI: 0.30, (95%CI, 0.11–0.86), P = 0.01] or ARB [HR for ARNI vs. ARB: 0.21, (95%CI, 0.04–1.1), P = 0.05]. Additionally, patients aged no more than 60 years also exhibited reduced composite endpoints [HR for ARNI vs. ACEI: 0.21, (95%CI, 0.04–1.03), P = 0.06; HR for ARNI vs. ARB: 0.11, (95%CI, 0.03–0.46), P = 0.002]. Interestingly, female patients benefit more from ARNI than ACEI female patients [HR for ARNI vs. ACEI: 0.24, (95%CI, 0.08–0.74), P = 0.004] (Figure 4 and Table 3).

Discussion

In the present study to compare the long-term outcome of AMI patients using ARNI vs. ACEI/ARB, we found that ARNI was associated with less composite outcomes and cardiovascular death during the 2 year follow-up. Subgroup analysis indicated that AMI patients with LVEF no more than 40%, aged no more than 60 years or female tend to benefit more from taking ARNI. To our knowledge, this is the first study to investigate the long-term outcomes of ARNI vs. ACEI/ARB among AMI patients focusing on the real-world evidence.

Ventricular remodelling after AMI are the factors that determine the incidence of cardiac events and long-term
### Table 2 Cumulative incidence of primary and secondary endpoints among the ARNI, ACEI, and ARB groups

| Endpoint                        | ARNI       | ACEI       | ARB        | ARNI vs. ACEI | ACEI vs. ARB |
|---------------------------------|------------|------------|------------|---------------|--------------|
| No. of participants with events | 259        | 214        | 173        | 0.51 (0.27–0.95) | 0.02         |
| (Kaplan–Meier event rate)       |            |            |            | 0.47 (0.24–0.90) | 0.02         |
| Hazard ratio                    | (95%CI)    | P value    | (95%CI)    | P value       |              |
| Composite endpoint              |            |            |            | 0.47 (0.24–0.90) | 0.02         |
| Cardiovascular death            | 16 (6.18%) | 24 (11.21%)| 22 (12.72%)| 0.37 (0.18–0.82) | 0.01         |
| Myocardial infarction           | 9 (3.47%)  | 5 (2.34%)  | 8 (4.62%)  | 1.19 (0.39–3.57) | 0.78         |
| Heart failure                   | 8 (3.09%)  | 5 (2.34%)  | 8 (4.62%)  | 0.66 (0.24–1.80) | 0.42         |
| Hospitalization                 |            |            |            | 0.47 (0.24–0.90) | 0.02         |
| Ischaemic stroke                | 5 (1.93%)  | 5 (2.34%)  | 8 (4.62%)  | 0.76 (0.22–2.68) | 0.43         |
| Rehospitalization               | 22 (8.49%) | 18 (8.41%) | 14 (8.09%) | 0.95 (0.50–1.79) | 0.76         |

ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitors; CI, confidence interval.

### Figure 4
The primary composite endpoint in the pre-specified subgroups between the ARNI and ACEI/ARB groups. ACEI, angiotensin converting enzyme inhibitors; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitors; LVEF, left ventricular ejection fraction.
prognosis after AMI.\textsuperscript{17} Multiple factors, including sex, age, smoking, obesity, type of vascular lesions, and comorbidities, all contribute to the progression of HF after AMI, making the HF rate after myocardial infarction continued to increase event after percutaneous coronary intervention.\textsuperscript{18} Recently, the application of ARNI for reversing cardiac remodelling has attracted a great deal of attention. Sacubitril/valsartan simultaneously blocks the effects of the angiotensin type 1 receptor through valsartan and inhibits the breakdown of several vasoactive peptides that are degraded by neprilysin.\textsuperscript{19} Meta-analysis also indicates that ARNI can improve functional capacity and cardiac reverse remodelling in HFrEF patients compared with ACEI/ARB.\textsuperscript{20} Although previous controlled trials validated the benefits of ARNI compared with ACEI/ARB to reduce morbidity and mortality in HFrEF patients, the real-world data for AMI patients are still inadequate.

The major novelty is that the present study innovatively investigated the long-term cardiovascular effect of ARNI vs. ACEI or ARB among AMI patients based on a real-world experience. It is speculated that sacubitril/valsartan could benefit MI and HF by simultaneously blocking the up-regulated RAAS in MI while augmenting the salutary effects of the natriuretic peptides. Animal studies have indicated that sacubitril/valsartan averts adverse post-infarction ventricular remodelling and preserves systolic function.\textsuperscript{21} The PARADISE-MI trail, aiming to ascertain whether sacubitril/valsartan prevents the development of HF and reduces cardiovascular deaths when compared with a previously proven ACEI/ARB among AMI patients, has also been recently released, although without reaching its primary endpoint.\textsuperscript{15} In our study, it is shown that ARNI offers incremental clinical value for the prevention of cardiovascular death. The difference of our results might be because the primary endpoints of our study include the first onset as well as the recurrence of heart failure. As a result, we suggest that, it is valuable to further in-depth investigate whether ARNI could ‘rescue’ the MI-induced HFrEF and reverse the ventricular remodelling as evaluated by the echocardiography. In addition, long-term follow-up study as well as subgroup analysis from PARADISE-MI are also needed.

When comparing the primary composite endpoint in the pre-specified subgroups, it is indicated that patients with cardiac ejection fraction no more than 40% and aged no more than 60 years tend to benefit more from ARNI as compared with ACEI/ARB. Clinical trials have proved that the benefits of ARNI are most clearly evident in patients with LVEF below normal.\textsuperscript{10–14} These subgroup data should be taken with caution and warrant large sample validation but might indicate preference for clinical treatments. Interestingly, it is also shown that female AMI patients utilizing ARNI exhibited a better long-term outcome as compared with ACEI users. This correlates to the findings from the PARAGON study\textsuperscript{22} that ARNI treatment reduced the primary endpoint (total hospitalization for HF and risk of cardiovascular death) by 27% among female patients with HF with preserved ejection fraction. This indicates that ARNI might exert long-term cardiovascular benefits on female patients, and the exact mechanism remains to be explored.\textsuperscript{23}

### Study limitations

Our findings should be interpreted in the context of several potential limitations. As this is a retrospective study, the follow-up data of echocardiography and New York Heart Association functional class are not complete, although these variables have been shown to contribute to the prognostic information in HF and AMI. Next, the achieved dose levels of ARNI, ACEI, or ARB are not available so that it is not possible to match the dose levels of the three groups. The incomplete information about the patients’ medication compliance, especially to the ARNI or ACEI/ARB, might also affect the endpoints. As this is a single-centre study, the follow-up results are not broadly representative.

---

**Table 3** Cumulative incidence of primary composite endpoint in the pre-specified subgroups between the ARNI, ACEI, and ARB groups

| Subgroup     | ARNI n/N (%) | ACEI n/N (%) | ARB n/N (%) | Hazard ratio (95%CI) | P value | Hazard ratio (95%CI) | P value |
|--------------|--------------|--------------|-------------|----------------------|---------|----------------------|---------|
| All patients | 16/259 6.18  | 24/212 6.18  | 22/173 12.72| 0.71 (0.33–1.41)     | 0.27    | 0.48 (0.23–1.00)     | 0.03    |
| LVEF >40%    | 11/200 5.50  | 14/174 8.05  | 18/157 11.46| 0.64 (0.29–1.41)     | 0.27    | 0.48 (0.23–1.00)     | 0.03    |
| LVEF ≤40%    | 5/59 8.47   | 10/38 26.32  | 4/16 25.00  | 0.30 (0.11–0.86)     | 0.01    | 0.21 (0.04–1.1)      | 0.05    |
| Age ≤60 years| 1/115 0.87  | 5/102 4.90  | 8/76 10.53  | 0.21 (0.04–1.03)     | 0.06    | 0.11 (0.03–0.46)     | 0.002   |
| Age 60–75 years| 11/113 9.73 | 8/74 10.81  | 10/68 14.71 | 0.89 (0.35–2.24)     | 0.80    | 0.72 (0.30–1.75)     | 0.37    |
| Age >75 years| 4/31 12.90  | 11/36 30.56  | 14/29 48.28 | 0.44 (0.15–1.24)     | 0.06    | 0.71 (0.17–3.00)     | 0.69    |

ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitors; CI, confidence interval; LVEF, left ventricular ejection fraction.

DOI: 10.1002/ehf2.13644

ESC Heart Failure 2021; 8: 4607–4616

J. She et al.
Conclusion

This retrospective study based on real-world data suggests that ARNI can reduce the long-term adverse cardiovascular outcomes as compared with ACEI or ARB users. These improvements were largely driven by a substantial reduction of cardiovascular death after ARNI initiation. Subgroup analysis further indicates that ARNI are more likely to benefit patients with LVEF less than 40% and aged less than 60 years.

Acknowledgements

The authors wish to acknowledge the assistance of Biobank from the First Affiliated Hospital of Xi’an Jiaotong University with the data extraction and preparation of the manuscript.

Conflict of interest

None declared.

Funding

This study was supported by National Natural Science Foundation of China (81800390, 82170464, 92049203 and 81941005), Key Research and Development Program of Shaanxi (Program 2020KW-049 and 2021KWZ-25), the Fundamental Research Funds for the Central Universities in China (11913291000056), and the Clinical Research Award of the First Affiliated Hospital of Xi’an Jiaotong University, China (XJTU1AF-CRF-2018-025 and XJTU1AF-CRF-2017-006).

Authors’ contributions

JS, HL, and ZY participated in the design of the study. JS, BL, and HL collected the patients’ data and did the follow-up. BZ, BL, and GTJ performed the statistical analysis. YL, HW, and CW finished the patients’ follow-up. JS and BL drafted the manuscript. All authors approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from all study participants, with ethnic committee approval at the First Affiliated Hospital of Xi’an Jiaotong University.

Consent for publication

All authors have reviewed the final version of the manuscript and approve it for publication.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Propensity Score Matching.

References

1. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011; 4: 98–108.
2. She J, Deng Y, Wu Y, Xia Y, Li H, Liang X, Shi R, Yuan Z. Hemoglobin A1c is associated with severity of coronary artery stenosis but not with long term clinical outcomes in diabetic and non-diabetic patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Diabetol 2017; 16: 97.
3. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000; 35: 569-582. doi:10.1016/s0735-1097(99)00630-0
4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride P, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the american College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 70: 776–803.
5. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Cagnotto ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Wiring J, ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the european Society of Cardiology (ESC). Eur Heart J 2018; 39: 119–177.
6. Seferovic PM, Ponikowski P, Anker SD, Bayersachs J, Chinconel O, Cleland JGF, Boer RA, Drexel H, Ben Gal T, Hill L,

DOI: 10.1002/ehf2.13644
Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. an expert consensus meeting report of the European Society of cardiology. *Eur J Heart Fail* 2019; 21: 1169–1186.

Yalta K, Yilmaz MB, Yalta T, Palabiyik O, Taylan G, Zorkun C. Late versus early myocardial remodeling after acute myocardial infarction: a comparative review on mechanistic insights and clinical implications. *J Cardiovasc Pharmacol Ther* 2020; 25: 15–26.

Pradhan A, Vohra S, Sethi R. Eplerenone: the multifaceted drug in cardiovascular pharmacology. *J Pharm Bioooled Sci* 2020; 12: 381–390.

McMurray JJ, Packer M, Desai AS, Gong J, Lefkopwitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014; 371: 993-1004. doi:10.1056/NENJmoa1409077

Murphy SP, Prescott MF, Camacho A, Iyer SR, Maisel AS, Felker GM, Butler J, Piña IL, Ibrahim NE, Abbas C, Burnett JC, Jr, Solomon SD, Januzzi JL. Atrial natriuretic peptide and treatment with Sacubitril/Valsartan in heart failure with reduced ejection fraction. *JACC Heart Fail*. 2021; 9: 127–136.

Pina IL, Camacho A, Ibrahim NE, Abbas C, Camacho A, Ibrahim NE, Felker GM, Butler J, Maisel AS, Prescott MF, Williamson KM, Claggett BL, Desai AS, Solomon SD, Januzzi JL. PROVE-HF Investigators. Improvement of health status following initiation of Sacubitril/ Valsartan in heart failure and reduced ejection fraction. *JACC Heart Fail*. 2021; 9: 822–833.

Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD, PROVE-HF Investigators. Association of change in N-Terminal Pro-B-Type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. *JAMA*. 2019: 1–11.

Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF, EVALUATE-HF Investigators. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial. *JAMA*. 2019: 1–10.

Pascual-Figal D, Wachter R, Senni M, Bao W, Noé A, Schwende H, Butylín D, Prescott MF, Gniot J, Mozheiko M, Lelonek M, Domínguez AR, Horacek T, García del Rio E, Kobalava Z, Mueller CE, Cavusoglu Y, Straburszynska-Migaj E, Slanina M, vom Dahl J, Senni M, Ryding A, Moriarty A, Robles MB, Villota JM, Quintana AG, Nitschke T, Garcia Pinilla JM, Bonet LA, Chaaban S, Filali zaatari S, Spinjar J, Mustial W, Abdellahi K, Belohlavек J, Fehske W, Bost MC, Hoegalmén G, Leiro MC, Ozcan IT, Mullens W, Kryza R, al-Ani R, Loboz-Grudzien K, Ermoshkina L, Hojerova S, Fernandez AA, Spinario L, Lapp H, Bulte E, Almeida F, Veshnevsky A, Belicova M, Pascual D, Witte K, Wong K, Droogwe D, Delforge M, Peterka M, Olbrich HG, Carugo S, Nessler J, McGill TH, Huelg B, Akin I, Moreira I, Baglikov A, Thambirajah J, Hayes C, Barrionuevo MR, Yigit Z, Kayu H, Klízma Z, Radvan M, Kadel C, Landmesser U, di Tano G, Lisik MB, Fonseca C, Oliveira L, Marques I, Santos LM, Lenner E, Letavay P, Bueno MG, Mota P, Wong A, Bailey K, Foley P, Hasbani E, Virani S, Massili TA, al-Saif S, Taborsky M, Kaislerova M, Motsovsk M, Cohen AA, Logeart D, Edemans D, Ferreira D, Brito D, Kycina P, Bollano E, Basílio EG, Rubio LF, Aguado MG, Schiavi LB, Zivano DF, Lenn O, el Sayed S, Polasek R, Houra M, Trübouiloy C, Seronde MF, Gallner M, Noutsias M, Schwimmbeck P, Vaipio I, Westerman D, Pulignano G, Vegsundvaag J, da Silva Antunes JA, Monteiro P, Stevlik J, Menegaz M, Kadel C, Landmesser U, di Tano G, Lisik MB, Fonseca C, Oliveira L, Marques I, Santos LM, Lenner E, Letavay P, Bueno MG, Mota P, Wong A, Bailey K, Foley P, Hasbani E, Virani S, Massili TA, al-Saif S, Taborsky M, Kaislerova M, Motsovsk M, Cohen AA, Logeart D, Edemans D, Ferreira D, Brito D, Kycina P, Bollano E, Basílio EG, Rubio LF, Aguado MG, Schiavi LB, Zivano DF, Lenn O, el Sayed S, Polasek R, Houra M, Trübouiloy C, Seronde MF, Gallner M, Noutsias M, Schwimmbeck P, Vaipio I, Westerman D, Pulignano G, Vegsundvaag J, da Silva Antunes JA, Monteiro P, Stevlik J, Gualcoceva E, Hulkoova B, Castro Fernández Ad, Davies C, Squire I, Meyers P, Sheppard R, Sahin T, Sochor K, de Greter G, Wachter R, Schmeisser A, Weil J, Soares AO, Vasiljeva OB, Oshurovk A, Sunderland SJ, Glover J, Exequiel T, Decoulx E, Meyer S, Muenzel T, Fries F, Arbolishvili G, Tokarcikova A, Karlstrom P, Trullas Vila JC, Perez GP, Kranz Karaci Y, Nageh T, Alasia DC, Reifert J, al-Buraiki J, Karabsheh S. NT-proBNP response to Sacubitril/Valsartan in hospitalized heart failure patients with reduced ejection fraction: TRANSITION study. *JACC Heart Fail*. 2020; 8: 822–833.

Jering KS, Claggett B, Pfeiffer MA, Granger C, Keber L, Lewis EF, Maggioni AP, Mann DJ, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Meer P, McMurray JJV, Anand IS, Solomon SD, Januzzi JL Jr, Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study Investigators. Sex-based differences in biomarkers, clinical characteristics, and prognostic measures for adults with acute ST-segment elevation myocardial infarction. *Zhonghua Xin Xue Guan Bing Za Zhi* 2018; 46: 849–856.

Jenca D, Melenovsky V, Stehlik J, Jenca D, Melenovsky V, Stehlik J, Stanek V, Kettner J, Kautzner J, Adamkova V, Wohlfahrt P. Heart failure after myocardial infarction: incidence and predictors. *ESC Heart Fail* 2021; 8: 222–237.

Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. *Am J Cardiol* 2006; 97: 13F–25F.

Bellas A, Mauro C, Barbato E, di Gioia G, Sorrentino D, Trimmero B, Morisco C. The rationale of neprilysin inhibition in prevention of myocardial ischemia-reperfusion injury during ST-elevation myocardial infarction. *Cells*. 2020; 9: 2134.

Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. *J Am Heart Assoc*. 2019; 8: e012277.

Torrado J, Cain C, Mauro AG, Romeo F, Ockaili R, Chau VQ, Nestler JA, Devarkonkda T, Ghosh S, Das A, Saloumi FN. Sacubitril/Valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits. *J Am Coll Cardiol* 2018; 72: 2342–2356.

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boysov SA, Comin-Colet J, Cleland J, Dünge HD, Gualcoceva E, Katova T, Kerr Sala JF, Leleok M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Leleok M, MP-PARAGON-HF Investigators and Committees. Angiotensin- neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med* 2019; 381: 1609-20. doi:10.1056/ NENJmoa1908655

Ibrahim NE, Pina IL, Camacho A, Piña IL, Camacho A, Bapat D, Felker GM, Maisel AS, Butler J, Prescott MF, Abbas CA, Solomon SD, Januzzi JL Jr, Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study Investigators. Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. *Eur J Heart Fail* 2020; 22: 2018–2025.